Heather H Cheng

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. doi Advanced clinical states in prostate cancer
    Heather H Cheng
    Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA 98109, USA
    Urol Clin North Am 39:561-71. 2012
  2. doi A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic Counseling
    Heather H Cheng
    Division of Oncology, Department of Medicine, University of Washington, Seattle, Washington
    Prostate 76:1303-11. 2016
  3. pmc Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer
    Michael T Schweizer
    Division of Oncology, Department of Medicine, University of Washington, Seattle, WA, 98109, USA
    Med Oncol 33:77. 2016
  4. pmc Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer
    Heather H Cheng
    Department of Medicine, Division of Oncology, University of Washington, Seattle, WA, USA Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Eur Urol 69:992-5. 2016
  5. pmc Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate
    Michael T Schweizer
    Department of Medicine, Division of Oncology, University of Washington, Seattle, WA, USA
    Oncotarget 7:82504-82510. 2016
  6. pmc Improved disease markers suggest dual response in a patient with metastatic castration resistant prostate cancer and chronic lymphocytic leukemia following active cellular immunotherapy
    Heather H Cheng
    University of Washington, Seattle, USA
    J Hematol Oncol 8:51. 2015
  7. pmc Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia
    Heather H Cheng
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    PLoS ONE 8:e69239. 2013

Collaborators

Detail Information

Publications7

  1. doi Advanced clinical states in prostate cancer
    Heather H Cheng
    Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA 98109, USA
    Urol Clin North Am 39:561-71. 2012
    ..The authors define the current disease states and discuss implications for prognosis and treatment decisions, as well as the limitations of existing classifications and emerging discoveries...
  2. doi A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic Counseling
    Heather H Cheng
    Division of Oncology, Department of Medicine, University of Washington, Seattle, Washington
    Prostate 76:1303-11. 2016
    ..The objective of this study was to determine current clinical utility of tNGS for prostate cancer management...
  3. pmc Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer
    Michael T Schweizer
    Division of Oncology, Department of Medicine, University of Washington, Seattle, WA, 98109, USA
    Med Oncol 33:77. 2016
    ..We did not observe a significant difference in toxicity between mHSPC and mCRPC patients receiving docetaxel. However, the small sample size and retrospective nature of this study limit our ability to draw definitive conclusions. ..
  4. pmc Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer
    Heather H Cheng
    Department of Medicine, Division of Oncology, University of Washington, Seattle, WA, USA Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Eur Urol 69:992-5. 2016
    ..The third patient had somatic BRCA2 homozygous copy loss. Biallelic BRCA2 inactivation in mCRPC warrants further exploration as a predictive biomarker for sensitivity to platinum chemotherapy. ..
  5. pmc Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate
    Michael T Schweizer
    Department of Medicine, Division of Oncology, University of Washington, Seattle, WA, USA
    Oncotarget 7:82504-82510. 2016
    ..Since hypermutation may predict for response to immune checkpoint blockade, the presence of dPC may be a rapid means to enrich populations for further screening. Given our small sample size, these findings require replication...
  6. pmc Improved disease markers suggest dual response in a patient with metastatic castration resistant prostate cancer and chronic lymphocytic leukemia following active cellular immunotherapy
    Heather H Cheng
    University of Washington, Seattle, USA
    J Hematol Oncol 8:51. 2015
    ..This case report suggests that treatment with sipuleucel-T can rarely lead to PSA decline, may have dual activity against both prostate cancer and CLL, and that these findings warrant further investigation. ..
  7. pmc Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia
    Heather H Cheng
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    PLoS ONE 8:e69239. 2013
    ....